olaparib,abiraterone
astrazeneca,merck
['brca', 'propel', 'crpc']
excellent presentation by dr. julie graf about parpi in mcrpc. highlighting intriguing data with 35% of patients with undetermined brca mutation in propel, and interestingly the benefit was in between the mutated and non-mutated groups. we should insist in hrr testing. #asco23 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer